Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies
- PMID: 11914295
- DOI: 10.1093/ije/31.1.59
Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies
Abstract
Background: Elevated concentrations of homocyst(e)ine are thought to increase the risk of vascular diseases including coronary heart disease and cerebrovascular disease.
Methods: We searched MEDLINE (1966-1999), EMBASE (1974-1999), SciSearch (1974- 1999), and Dissertation Abstracts (1999) for articles and theses about homocyst(e)ine concentration and coronary heart disease and cerebrovascular disease.
Results: We included 57 publications (3 cohort studies, 12 nested case-control studies, 42 case-control studies) that reported results on 5518 people with coronary heart disease (11,068 control subjects) and 1817 people with cerebrovascular disease (4787 control subjects) in our analysis. For coronary heart disease, the summary odds ratios (OR) for a 5-micromol/l increase in homocyst(e)ine concentration were 1.06 (95% CI : 0.99-1.13) for 2 publications of cohort studies, 1.23 (95% CI : 1.07-1.41) for 10 publications of nested case-control studies, and 1.70 (95% CI : 1.50-1.93) for 26 publications of case-control studies. For cerebrovascular disease, the summary OR for a 5-micromol/l increase in homocyst(e)ine concentration were 1.10 (95% CI : 0.94-1.28) for 2 publications of cohort studies, 1.58 (95% CI : 1.35-1.85) for 5 publications of nested case-control studies, and 2.16 (95% CI : 1.65-2.82) for 17 publications of case-control studies.
Conclusions: Prospective studies offer weaker support than case-control studies for an association between homocyst(e)ine concentration and cardiovascular disease. Although other lines of evidence support a role for homocyst(e)ine in the pathogenesis of cardiovascular disease, more information from prospective epidemiological studies or clinical trials is needed to clarify this role.
Comment in
-
Commentary: an updated review of the published studies of homocysteine and cardiovascular disease.Int J Epidemiol. 2002 Feb;31(1):70-1. doi: 10.1093/ije/31.1.70. Int J Epidemiol. 2002. PMID: 11914296 No abstract available.
-
Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects.Int J Epidemiol. 2002 Dec;31(6):1268-72; author reply 1271-2. doi: 10.1093/ije/31.6.1268. Int J Epidemiol. 2002. PMID: 12540734 No abstract available.
Similar articles
-
Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial.Indian Heart J. 2000 Nov-Dec;52(7 Suppl):S44-52. Indian Heart J. 2000. PMID: 11339440 Clinical Trial.
-
Potential clinical and economic effects of homocyst(e)ine lowering.Arch Intern Med. 2000 Dec 11-25;160(22):3406-12. doi: 10.1001/archinte.160.22.3406. Arch Intern Med. 2000. PMID: 11112233
-
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.Ann Intern Med. 1999 Sep 7;131(5):363-75. doi: 10.7326/0003-4819-131-5-199909070-00008. Ann Intern Med. 1999. PMID: 10475890 Review.
-
Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey.Am Heart J. 2000 Mar;139(3):446-53. doi: 10.1016/s0002-8703(00)90088-7. Am Heart J. 2000. PMID: 10689259
-
Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases.J Nutr. 1996 Apr;126(4 Suppl):1238S-43S. doi: 10.1093/jn/126.suppl_4.1238S. J Nutr. 1996. PMID: 8642463 Review.
Cited by
-
Walking and Activeness: The First Step toward the Prevention of Strokes and Mental Illness.Comput Intell Neurosci. 2022 Mar 14;2022:3440437. doi: 10.1155/2022/3440437. eCollection 2022. Comput Intell Neurosci. 2022. Retraction in: Comput Intell Neurosci. 2023 Oct 4;2023:9834938. doi: 10.1155/2023/9834938. PMID: 35321459 Free PMC article. Retracted.
-
Twelve-Week Daily Consumption of ad hoc Fortified Milk with ω-3, D, and Group B Vitamins Has a Positive Impact on Inflammaging Parameters: A Randomized Cross-Over Trial.Nutrients. 2020 Nov 22;12(11):3580. doi: 10.3390/nu12113580. Nutrients. 2020. PMID: 33266447 Free PMC article. Clinical Trial.
-
Association between shift work and hyperhomocysteinemia in male workers.Ann Occup Environ Med. 2019 May 1;31:e1. doi: 10.35371/aoem.2019.31.e1. eCollection 2019. Ann Occup Environ Med. 2019. PMID: 31543962 Free PMC article.
-
Potential Anti-Inflammatory Treatment of Ischemic Heart Disease.Med Arch. 2018 Apr;72(2):94-98. doi: 10.5455/medarh.2018.72.94-98. Med Arch. 2018. PMID: 29736096 Free PMC article.
-
Homocysteine-lowering interventions for preventing cardiovascular events.Cochrane Database Syst Rev. 2017 Aug 17;8(8):CD006612. doi: 10.1002/14651858.CD006612.pub5. Cochrane Database Syst Rev. 2017. PMID: 28816346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources